Correlation of circulating dehydroepiandrosterone with activated proteinC generation and carotid intima-media thickness in male patients with Type2 diabetes

Diabetic Medicine

Volumn 29, Issue 7, 2012, Pages

  Suzuki, T ^a   Yano, Y ^a   Sakamoto, M ^a   Uemura, M ^a   Yasuma, T ^a   Onishi, Y ^a   Sasaki, R ^a   Matsumoto, K ^a   Hayashi, T ^a   Maruyama Furuta, N ^a   Akatsuka, H ^a   Gabazza, E C ^a   Sumida, Y ^a   Takei, Y ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Androgens; Atherosclerosis; Inflammation; Type2 diabetes

Indexed keywords

ACTIVATED PROTEIN C; C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRASTERONE;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DEHYDROEPIANDROSTERONE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MALE; MIDDLE AGED; PROTEIN C;

EID: 84862670011     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03573.x     Document Type: Article

References (30)

1. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-876.
2. Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci 1995; 774: 271-280.
3. Simoncini T, Genazzani AR. Dehydroepiandrosterone, the endothelium, and cardiovascular protection. Endocrinology 2007; 148: 3065-3067.
4. Brignardello E, Runzo C, Aragno M, Catalano MG, Cassader M, Perin PC et al. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type2 diabetic patients. Diabetes Care 2007; 30: 2922-2927.
5. Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF et al. Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis 2007; 190: 90-99.
6. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995; 332: 677-678.
7. Esmon CT. Coagulation inhibitors in inflammation. Biochem Soc Trans 2005; 33: 401-405.
8. Dahlback B, Villoutreix BO. The anticoagulant proteinC pathway. FEBS Lett 2005; 579: 3310-3316.
9. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell proteinC receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001; 159: 797-802.
10. Lentz SR, Fernandez JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR et al. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the proteinC system. Arterioscler Thromb Vasc Biol 1999; 19: 1744-1750.
11. Matsumoto K, Yano Y, Gabazza EC, Araki R, Bruno NE, Suematsu M et al. Inverse correlation between activated proteinC generation and carotid atherosclerosis in Type2 diabetic patients. Diabet Med 2007; 24: 1322-1328.
12. Yamaguchi Y, Tanaka S, Yamakawa T, Kimura M, Ukawa K, Yamada Y et al. Reduced serum dehydroepiandrosterone levels in diabetic patients with hyperinsulinaemia. Clin Endocrinol (Oxf) 1998; 49: 377-383.
13. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investigation 2010; 1: 212-228.
14. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
15. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y et al. Decreased endogenous secretory advanced glycation end product receptor in type1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005; 28: 2716-2721.
16. Ueshiba H, Shimizu Y, Hiroi N, Yakushiji F, Shimojo M, Tsuboi K et al. Decreased steroidogenic enzyme 17, 20-lyase and increased 17-hydroxylase activities in type2 diabetes mellitus. Eur J Endocrinol 2002; 146: 375-380.
17. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632-3639.
18. Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 2000; 49: S43-S56.
19. Aragno M, Parola S, Brignardello E, Mauro A, Tamagno E, Manti R et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 2000; 49: 1924-1931.
20. Yamakawa T, Ogihara K, Nakamura M, Utsunomiya H, Kadonosono K, Kishikawa S et al. Effect of dehydroepiandrosterone on atherosclerosis in apolipoproteinE-deficient mice. J Atheroscler Thromb 2009; 16: 501-508.
21. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2, 3). J Biol Chem 2002; 277: 21379-21388.
22. Liu D, O'Leary B, Iruthayanathan M, Love-Homan L, Perez-Hernandez N, Olivo HF et al. Evaluation of a novel photoactive and biotinylated dehydroepiandrosterone analog. Mol Cell Endocrinol 2010; 26: 56-62.
23. Sandusky G, Berg DT, Richardson MA, Myers L, Grinnell BW. Modulation of thrombomodulin-dependent activation of human proteinC through differential expression of endothelial Smads. J Biol Chem 2002; 277: 49815-49819.
24. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 1999; 42: 222-232.
25. Patel S, Santani D. Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 2009; 61: 595-603.
26. Wang L, Hao Q, Wang YD, Wang WJ, Li DJ. Protective effects of dehydroepiandrosterone on atherosclerosis in ovariectomized rabbits via alleviating inflammatory injury in endothelial cells. Atherosclerosis 2011; 214: 47-57.
27. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-κB. Blood 2005; 105: 3910-3917.
28. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Emerging Risk Factors Collaboration. Lancet 2010; 375: 132-140.
29. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326.
30. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 2009; 117: 95-109.